Oral Vitamin D Supplementation and Clinical Outcomes of Intravitreal Bevacizumab Injection for Macular Edema Secondary to Retinal Vein Occlusions
Abstract Purpose: To evaluate the therapeutic response of retinal vein occlusion (RVO) to intravitreal bevacizumab (IVB) with and without concomitant vitamin D supplementation. Method: Seventy eyes of 68 patients with macular edema associated with branch retinal vein occlusion (BRVO) and central ret...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Knowledge E
2022-08-01
|
| Series: | Journal of Ophthalmic & Vision Research |
| Subjects: | |
| Online Access: | https://doi.org/10.18502/jovr.v17i3.11575 |
| _version_ | 1811332365757186048 |
|---|---|
| author | Saeed Karimi Farhad Parvizi Amir Arabi Toktam Shahraki Sare Safi |
| author_facet | Saeed Karimi Farhad Parvizi Amir Arabi Toktam Shahraki Sare Safi |
| author_sort | Saeed Karimi |
| collection | DOAJ |
| description | Abstract Purpose: To evaluate the therapeutic response of retinal vein occlusion (RVO) to intravitreal bevacizumab (IVB) with and without concomitant vitamin D supplementation. Method: Seventy eyes of 68 patients with macular edema associated with branch retinal vein occlusion (BRVO) and central retinal vein occlusion (CRVO) received three monthly IVB injections. Patients with serum 25-hydroxyvitamin D (25(OH) D) higher than 30 ng/ml were considered as the sufficient group. Cases with serum 25(OH) D levels below 30 ng/ml were randomized into the treatment and control groups. The control group received 50,000 IU of oral vitamin D, weekly for two months. One month after the last IVB injection, best-corrected visual acuity (BCVA) and central macular thickness (CMT) were measured and compared with the preinjection values. Results: While 43 eyes (61.4%) of 42 patients had BRVO, 27 eyes (38.6%) of 26 patients had CRVO. In BRVO patients, changes of CMT and BCVA were not significantly different between the sufficient, control, and treatment groups (P = 0.58 and 0.64, respectively). In the CRVO group, CMT reduction in the control group was significantly less than the sufficient and treatment groups (P = 0.048). In addition, improvement of BCVA in the control group was significantly less (P = 0.036) than the sufficient and treatment groups. Conclusion: Oral vitamin D supplement therapy may improve anatomical and functional outcomes in patients with CRVO and vitamin D deficiency. |
| first_indexed | 2024-04-13T16:34:49Z |
| format | Article |
| id | doaj.art-01b1998d70d640aa8e6b9a12068280cf |
| institution | Directory Open Access Journal |
| issn | 2008-2010 2008-322X |
| language | English |
| last_indexed | 2024-04-13T16:34:49Z |
| publishDate | 2022-08-01 |
| publisher | Knowledge E |
| record_format | Article |
| series | Journal of Ophthalmic & Vision Research |
| spelling | doaj.art-01b1998d70d640aa8e6b9a12068280cf2022-12-22T02:39:27ZengKnowledge EJournal of Ophthalmic & Vision Research2008-20102008-322X2022-08-0117337638310.18502/jovr.v17i3.11575jovr.v17i3.11575Oral Vitamin D Supplementation and Clinical Outcomes of Intravitreal Bevacizumab Injection for Macular Edema Secondary to Retinal Vein OcclusionsSaeed Karimi0Farhad Parvizi1Amir Arabi2Toktam Shahraki3Sare Safi4 Ophthalmic Research Center, Research Institute for Ophthalmology and Vision Science, Shahid Beheshti University of Medical Sciences, Tehran, Iran Department of Ophthalmology, Torfeh Medical Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran Department of Ophthalmology, Torfeh Medical Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran Department of Ophthalmology, Torfeh Medical Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran Ophthalmic Epidemiology Research Center, Research Institute for Ophthalmology and Vision Science, Shahid Beheshti University of Medical Sciences, Tehran, IranAbstract Purpose: To evaluate the therapeutic response of retinal vein occlusion (RVO) to intravitreal bevacizumab (IVB) with and without concomitant vitamin D supplementation. Method: Seventy eyes of 68 patients with macular edema associated with branch retinal vein occlusion (BRVO) and central retinal vein occlusion (CRVO) received three monthly IVB injections. Patients with serum 25-hydroxyvitamin D (25(OH) D) higher than 30 ng/ml were considered as the sufficient group. Cases with serum 25(OH) D levels below 30 ng/ml were randomized into the treatment and control groups. The control group received 50,000 IU of oral vitamin D, weekly for two months. One month after the last IVB injection, best-corrected visual acuity (BCVA) and central macular thickness (CMT) were measured and compared with the preinjection values. Results: While 43 eyes (61.4%) of 42 patients had BRVO, 27 eyes (38.6%) of 26 patients had CRVO. In BRVO patients, changes of CMT and BCVA were not significantly different between the sufficient, control, and treatment groups (P = 0.58 and 0.64, respectively). In the CRVO group, CMT reduction in the control group was significantly less than the sufficient and treatment groups (P = 0.048). In addition, improvement of BCVA in the control group was significantly less (P = 0.036) than the sufficient and treatment groups. Conclusion: Oral vitamin D supplement therapy may improve anatomical and functional outcomes in patients with CRVO and vitamin D deficiency.https://doi.org/10.18502/jovr.v17i3.1157525-hydroxyvitamin dbevacizumabinsufficiencyintravitrealmacular edema, retinal vein occlusion |
| spellingShingle | Saeed Karimi Farhad Parvizi Amir Arabi Toktam Shahraki Sare Safi Oral Vitamin D Supplementation and Clinical Outcomes of Intravitreal Bevacizumab Injection for Macular Edema Secondary to Retinal Vein Occlusions Journal of Ophthalmic & Vision Research 25-hydroxyvitamin d bevacizumab insufficiency intravitreal macular edema, retinal vein occlusion |
| title | Oral Vitamin D Supplementation and Clinical Outcomes of Intravitreal Bevacizumab Injection for Macular Edema Secondary to Retinal Vein Occlusions |
| title_full | Oral Vitamin D Supplementation and Clinical Outcomes of Intravitreal Bevacizumab Injection for Macular Edema Secondary to Retinal Vein Occlusions |
| title_fullStr | Oral Vitamin D Supplementation and Clinical Outcomes of Intravitreal Bevacizumab Injection for Macular Edema Secondary to Retinal Vein Occlusions |
| title_full_unstemmed | Oral Vitamin D Supplementation and Clinical Outcomes of Intravitreal Bevacizumab Injection for Macular Edema Secondary to Retinal Vein Occlusions |
| title_short | Oral Vitamin D Supplementation and Clinical Outcomes of Intravitreal Bevacizumab Injection for Macular Edema Secondary to Retinal Vein Occlusions |
| title_sort | oral vitamin d supplementation and clinical outcomes of intravitreal bevacizumab injection for macular edema secondary to retinal vein occlusions |
| topic | 25-hydroxyvitamin d bevacizumab insufficiency intravitreal macular edema, retinal vein occlusion |
| url | https://doi.org/10.18502/jovr.v17i3.11575 |
| work_keys_str_mv | AT saeedkarimi oralvitamindsupplementationandclinicaloutcomesofintravitrealbevacizumabinjectionformacularedemasecondarytoretinalveinocclusions AT farhadparvizi oralvitamindsupplementationandclinicaloutcomesofintravitrealbevacizumabinjectionformacularedemasecondarytoretinalveinocclusions AT amirarabi oralvitamindsupplementationandclinicaloutcomesofintravitrealbevacizumabinjectionformacularedemasecondarytoretinalveinocclusions AT toktamshahraki oralvitamindsupplementationandclinicaloutcomesofintravitrealbevacizumabinjectionformacularedemasecondarytoretinalveinocclusions AT saresafi oralvitamindsupplementationandclinicaloutcomesofintravitrealbevacizumabinjectionformacularedemasecondarytoretinalveinocclusions |